Interventions for Infection and Inflammation-Induced Preterm Birth: a Preclinical Systematic Review

Faith A Miller1, Adalina Sacco1, Anna L David1,2

  • 1Elizabeth Garrett Anderson Institute for Women's Health, University College London, 86-96 Chenies Mews, London, WC1E 6HX, UK.

Insights

Promising anti-inflammatory interventions show potential for preventing preterm birth in animal models. Further research requires standardized models to improve clinical translation for infection-induced premature births.

Area of Science:

  • Reproductive Biology
  • Immunology
  • Pharmacology

Background:

  • Spontaneous preterm birth (before 37 weeks gestation) is often linked to infection and inflammation.
  • Current treatments for infection-related preterm birth are limited, necessitating the development of new therapeutic strategies.
  • Animal models are crucial for pre-clinical research into potential interventions.

Approach:

  • A PROSPERO-registered preclinical systematic review following PRISMA guidelines.
  • Searched PubMed, EMBASE, and Web of Science for studies on animal models, preterm birth, inflammation, and therapeutics.
  • Included 23 quantitative, peer-reviewed, controlled studies using prenatal interventions in animal models.

Key Points:

  • Twenty-four interventions were evaluated, primarily in mouse models using lipopolysaccharide or Escherichia coli to induce preterm birth.
  • Eighty-three percent of interventions significantly prolonged gestational length, and 87% reduced maternal inflammation markers.
  • Interventions targeting interleukin-1, interleukin-6, and toll-like receptors demonstrated significant therapeutic potential.

Conclusions:

  • Interventions targeting inflammation show significant therapeutic promise for preventing preterm birth in preclinical models.
  • Standardization of preterm birth models (infectious agent, dose, timing, outcomes) is critical for reproducibility and clinical translation.
  • Further research is needed to refine these interventions and facilitate their move to clinical application.